International Kidney Cancer Symposium | Conferences

November 08, 2021

Compared with systemic therapy administered after cytoreductive nephrectomy, active surveillance was an option for some patients with metastatic renal cell carcinoma.

November 07, 2021

Compared with sunitinib, the combination of nivolumab an ipilimumab produced better long-term responses, with overall survival approaching 5 years.

November 07, 2021

New findings suggest that understanding subtypes of non-clear cell renal cell carcinoma is important for personalizing treatment.

November 06, 2021

James Brugarolas, MD, PhD, discusses updated survival data in patients with metastatic renal cell carcinoma.

November 06, 2021

The frontline combination of lenvatinib and pembrolizumab is under investigation as a treatment option for patients with non-clear cell renal cell carcinoma in the recently launched phase 2 KEYNOTE-B61 trial.

November 06, 2021

While immunotherapy has high and durable response rates, most patients die of the disease.

November 06, 2021

During a presentation at the 2021 International Kidney Cancer Symposium, Bradley McGregor, MD, discussed analyses of outcomes based on histology in major RCC clinical trials, and how this approach will shape the future of treatment.

November 05, 2021

Naomi B. Haas, MD, medical oncologist, discusses the potential benefits of lenvatinib for the treatment of renal cell carcinoma.

November 05, 2021

Limited data exists on the effects of palliative care in patients with kidney cancer, and more research is needed.

November 07, 2020

Investigators of the CheckMate 920 trial found no differences in safety signals or responses with modified dosing of nivolumab and ipilimumab compared with the standard dose in patients with advanced renal cell carcinoma treated in the frontline.